Biotech Bullish Stocks: Merrimack Pharmaceuticals (NASDAQ:MACK), Sarepta Therapeutics (NASDAQ:SRPT), Northwest Biotherapeutics (NASDAQ:NWBO), Progenics Pharmaceuticals (NASDAQ:PGNX)



Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 6.15% in last session and finished the day at $5.35. Traded volume was 885.2K shares in the last session and the average volume of the stock remained 1.66million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.50%.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. (NASDAQ:SRPT) common stock between July 24, 2013 through November 12, 2013. Sarepta Therapeutics Inc (NASDAQ:SRPT) rose 6.99 percent to $25.71 Tuesday on volume of 903.2K shares. The intra-day range of the stock was $24.26 to $25.98. Sarepta Therapeutics Inc (NASDAQ:SRPT) has a market capitalization of $971.20million.

Northwest Biotherapeutics Inc (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after Northwest Biotherapeutics Inc (NASDAQ: NWBO)’s public presentation of significant positive news about all of the Company’s programs. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s stock on Apr 01, 2014 reported a increase of 6.22% to the closing price of $7.69. Its fifty two weeks range is $3.10 -$10.64. The total market capitalization recorded $333.77million. The overall volume in the last trading session was 965.5K shares. In its share capital, NMBO has 43.40million outstanding shares.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals Inc (NASDAQ:PGNX). On Tuesday, shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) advanced 6.36% to close the day at $4.35. Company return on investment (ROI) is -53.30% and its monthly performance is recorded as -7.45%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly revenue growth is -18.84%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone